BDBM296512 US10112942, Example 246::US10137124, Example 246::US10172851, Example 246::US10555944, Example 246::US10953005, Example 246

SMILES COC(C)(C)COc1cc(-c2ccc(nc2)N2CCNCC2)c2c(cnn2c1)C#N

InChI Key InChIKey=HBEBEEKNAYNIGR-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 296512   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 414nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 414nMpH: 7.4Assay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 414nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Array Biopharma

US Patent
LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 414nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 414nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
US Patent

LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 7.84E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2019
Entry Details
US Patent

LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 7.84E+3nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2019
Entry Details
US Patent

LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 7.84E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay tech...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/30/2019
Entry Details
US Patent

LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 7.84E+3nMAssay Description:RET: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE -TK assay...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/28/2021
Entry Details
US Patent

LigandPNGBDBM296512(US10112942, Example 246 | US10137124, Example 246 ...)
Affinity DataIC50: 7.84E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2020
Entry Details
US Patent